Bayer Schering Pharma
Employees: 38,000
Business activities in more than 100 countries
Sales in 2007: EUR 10.267 billion
Headquarter: Berlin (Germany)
The 2006 acquisition of Schering was the largest purchase in Bayer’s history. The takeover led to the formation of Bayer Schering Pharma, a powerful, leading company that ranks among the top ten pharmaceutical specialists in the world and holds a strong position in Biologicals.
Schering brought a comprehensive range of products that ideally complement Bayer's portfolio to the new company. Bayer Schering Pharma is concentrating on
four strategic business units: Diagnostic Imaging, General Medicine, Specialty Medicine, and Women’s Healthcare.
The merger has produced a strong company with successful, well-established brands.
Its highest-selling products include:
- Yasmin® (hormonal contraceptive)
- Betaferon®/Betaseron® (multiple sclerosis)
- Kogenate® (hemophilia)
- Adalat® (hypertension)
- Avalox®/Avelox® (respiratory tract infections)
- Ciprobay®/Cipro® (infectious diseases, especially of the urinary tract)
- Mirena® (hormonal contraceptive)
- Levitra® (erectile dysfunction)
- Magnevist® (contrast medium for magnetic resonance imaging
- Glucobay® (diabetes)
- Health advice on Bayer Schering Pharma topics
- Bayer Schering Pharma research activities
- Internet portal of the Bayer Schering Pharma
